SELLAS Life Sciences Group, Inc. (SLS) Fundamental Analysis: Bull vs. Bear Case

SLS

SELLAS Life Sciences Group, Inc.

Fundamental data last updated:August 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

VALUATION

P/E

-53.75

Market Cap ($M USD)

$1.31B

Forward P/E

3.99 PEG

0.00 PRICE TO SALES

0.00 PRICE TO BOOK

14.74 EV / EBITDA

-50.44

5-Year Average P/E

Free Cash Flow Yield

-2.15%

DCF Value

$0.63

Graham Number

N/A

Price to FCF

-46.43

EV to FCF

-42.65

Earnings Yield

-1.86%

FCF Yield

-2.15%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.17

Next Year EPS Growth Estimate

$2.30

Next Year Revenue Growth Estimate

$575.93M

Return on Equity (ROE)

-47.12%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.01 Piotroski F-Score

2 Altman Z-Score

99.32 Return on Invested Capital (ROIC)

-29.21%

Current Ratio

17.22 Quick Ratio

17.22 Net Debt to EBITDA

4.46 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-0.16

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing SELLAS Life Sciences Group, Inc. significantly. With a DCF value far below the snapshot price, the stock appears overvalued. The Forward P/E of 1.37 suggests optimism for future earnings, yet the negative Earnings Yield and ROIC indicate poor current profitability. The Altman Z-score of 51.17 signals financial stability, but the negative Price to FCF ratio raises red flags about cash flow sustainability. Overall, the valuation is a paradox of future promise against present weakness.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, SELLAS is positioned to leverage AI advancements for drug discovery and personalized medicine. However, the company's current financial metrics suggest it may struggle to capitalize on these opportunities without significant strategic shifts. Its ability to adapt will depend heavily on management's execution of tech integration.

The Bull Case

For a value or GARP investor, SELLAS presents a compelling opportunity due to its low Forward PEG ratio, indicating potential undervaluation relative to growth. The company's minimal Debt/Equity ratio of 0.014 suggests financial prudence, while the high Altman Z-score underscores its stability. Despite a low Piotroski F-Score, the impressive Current Ratio of 10.72 highlights strong liquidity. These factors suggest a company with potential for efficient capital deployment and resilience in turbulent markets.

The Bear Case

The stock's glaring weaknesses cannot be ignored. A Price/Book ratio of 10.82 and a Price to FCF of -25.14 highlight severe overvaluation concerns. The negative EPS and ROIC reflect a company struggling to generate profits, while the zero gross profit margin indicates a lack of pricing power. Trading near its 52-week high, the stock appears technically overextended, posing significant downside risk.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$2.80

Institutional Ownership %

1-Year Beta

2.24 Insider Buying % (6 Mo)

Distance to 52-Week High

0.65%

Distance to 52-Week Low

84.86%

EARNINGS SURPRISE %

16.67%

50-DAY SMA

$5.49

200-DAY SMA

$3.42

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.